A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application

References

• Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20(12):3255–3264. doi:10.3748/wjg.v20.i12.3255
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434. doi:10.1038/nature06005
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603. doi:10.1038/35079107
   PubMed Web of Science ®Google Scholar
• Mirkov MU, Verstockt B, Cleynen I. Genetics of inflammatory bowel disease: beyond NOD2. Lancet Gastroenterol Hepatol. 2017;2(3):224–234. doi:10.1016/S2468-1253(16)30111-X
   PubMed Web of Science ®Google Scholar
• Nightingale SL. From the food and drug administration. JAMA. 1998;280(13):1128. doi:10.1001/jama.280.13.1128-JFD80009-2-1
   PubMedGoogle Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing crohn’s disease. Gastroenterology. 2021;160(7):2496–2508. doi:10.1053/j.gastro.2021.04.022
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi:10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–2030. doi:10.1016/S0140-6736(22)00467-6
   PubMed Web of Science ®Google Scholar
• Administration USFaD. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. FDA. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed May 25, 2022.
   Google Scholar
• Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379–1387. doi:10.1172/JCI76369
   PubMed Web of Science ®Google Scholar
• Biorender.com. “Nitric Oxide Synthesis 1”, by BioRender.com; 2022. Available from: https://app.biorender.com/biorender-templates. Accessed August 25, 2022.
   Google Scholar
• Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295–298. doi:10.1126/science.1139221
   PubMed Web of Science ®Google Scholar
• Venkataraman K, Lee YM, Michaud J, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102(6):669–676. doi:10.1161/CIRCRESAHA.107.165845
   PubMed Web of Science ®Google Scholar
• Pham TH, Baluk P, Xu Y, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010;207(1):17–27. doi:10.1084/jem.20091619
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005;5(7):560–570. doi:10.1038/nri1650
   PubMed Web of Science ®Google Scholar
• Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab. 2007;18(8):300–307. doi:10.1016/j.tem.2007.07.005
   PubMed Web of Science ®Google Scholar
• Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010;62(4):579–587. doi:10.1124/pr.110.003111
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16(5):495–503. doi:10.1016/j.autrev.2017.03.007
   PubMed Web of Science ®Google Scholar
• Argollo M, Furfaro F, Gilardi D, et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):413–420. doi:10.1080/14712598.2020.1732919
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Sphingosine-1-phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23(4):362–374. doi:10.1016/j.molmed.2017.02.002
   PubMed Web of Science ®Google Scholar
• Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta. 2008;1781(9):477–482. doi:10.1016/j.bbalip.2008.07.003
   PubMed Web of Science ®Google Scholar
• Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul. 2010;50(1):349–362. doi:10.1016/j.advenzreg.2009.10.024
   PubMedGoogle Scholar
• Vu TM, Ishizu AN, Foo JC, et al. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. Nature. 2017;550(7677):524–528. doi:10.1038/nature24053
   PubMed Web of Science ®Google Scholar
• Ito K, Anada Y, Tani M, et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun. 2007;357(1):212–217. doi:10.1016/j.bbrc.2007.03.123
   PubMed Web of Science ®Google Scholar
• Mendoza A, Bréart B, Ramos-Perez WD, et al. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep. 2012;2(5):1104–1110. doi:10.1016/j.celrep.2012.09.021
   PubMed Web of Science ®Google Scholar
• Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019;31(9):617–625. doi:10.1093/intimm/dxz037
   PubMed Web of Science ®Google Scholar
• Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP, Proia RL. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med. 2010;207(5):1113–1124. doi:10.1084/jem.20092210
   PubMed Web of Science ®Google Scholar
• Pereira JP, Xu Y, Cyster JG. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS One. 2010;5(2):e9277. doi:10.1371/journal.pone.0009277
   PubMed Web of Science ®Google Scholar
• Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309(5741):1735–1739. doi:10.1126/science.1113640
   PubMed Web of Science ®Google Scholar
• Hampton HR, Chtanova T. Lymphatic migration of immune cells. Front Immunol. 2019;10:1168. doi:10.3389/fimmu.2019.01168
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84–105. doi:10.1016/j.pharmthera.2007.04.006
   PubMed Web of Science ®Google Scholar
• Biorender.com. “Stimulated T Cells Migrate Out of Lymph Nodes and Enter Inflamed Tissue”, by BioRender.com; 2022. Available from: https://app.biorender.com/biorender-templates. Accessed August 25, 2022.
   Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355–360. doi:10.1038/nature02284
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453–21457. doi:10.1074/jbc.C200176200
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi:10.1056/NEJMoa0909494
   PubMed Web of Science ®Google Scholar
• Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S. Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother. 2011;2(1):49–51. doi:10.4103/0976-500X.77118
   PubMedGoogle Scholar
• Administration USFaD. FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gilenya-treat-multiple-sclerosis-pediatric-patients. Accessed May 28, 2022.
   Google Scholar
• Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4(7):1019–1025. doi:10.1111/j.1600-6143.2004.00476.x
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346–349. doi:10.1126/science.1070238
   PubMed Web of Science ®Google Scholar
• Singer II, Tian M, Wickham LA, et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol. 2005;175(11):7151–7161. doi:10.4049/jimmunol.175.11.7151
   PubMed Web of Science ®Google Scholar
• Sanna MG, Vincent KP, Repetto E, et al. Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction. Mol Pharmacol. 2016;89(1):176–186. doi:10.1124/mol.115.100222
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi:10.1056/NEJMoa0907839
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Center for drug evaluation and research. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000medr.pdf. Accessed July 28, 2022.
   Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859–873. doi:10.1007/s13311-017-0565-4
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT. Siponimod: first global approval. Drugs. 2019;79(9):1009–1015. doi:10.1007/s40265-019-01140-x
   Web of Science ®Google Scholar
• Scott LJ. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs. 2020;34(11):1191–1200. doi:10.1007/s40263-020-00771-z
   PubMed Web of Science ®Google Scholar
• Lamb YN. Ozanimod: first Approval. Drugs. 2020;80(8):841–848. doi:10.1007/s40265-020-01319-7
   PubMed Web of Science ®Google Scholar
• Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173(11):1778–1792. doi:10.1111/bph.13476
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016;374(18):1754–1762. doi:10.1056/NEJMoa1513248
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–1291. doi:10.1056/NEJMoa2033617
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer S, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021;15(7):1120–1129. doi:10.1093/ecco-jcc/jjab012
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819–828. doi:10.1016/S2468-1253(20)30188-6
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine NIoH. Induction Study #2 of oral ozanimod as induction therapy for moderately to severely active crohn’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT03440385. Accessed May 28, 2022.
   Google Scholar
• U.S. National Library of Medicine NIoH. Induction Study #1 of oral ozanimod as induction therapy for moderately to severely active crohn’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT03440372. Accessed May 28, 2022.
   Google Scholar
• U.S. National Library of Medicine NIoH. An extension study of oral ozanimod for moderately to severely active crohn’s disease. Available from: https://clinicaltrials.gov/ct2/show/NCT03467958. Accessed May 28, 2022.
   Google Scholar
• Markham A. Ponesimod: first Approval. Drugs. 2021;81(8):957–962. doi:10.1007/s40265-021-01523-z
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine NIoH. A phase 3 study of etrasimod in subjects with moderately to severely active ulcerative colitis. Available from: https://clinicaltrials.gov/ct2/show/NCT04176588. Accessed May 28, 2022.
   Google Scholar
• Antoniou E, Margonis GA, Angelou A, et al. The TNBS-induced colitis animal model: an overview. Ann Med Surg. 2016;11:9–15. doi:10.1016/j.amsu.2016.07.019
   PubMed Web of Science ®Google Scholar
• Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G135–46. doi:10.1152/ajpgi.90462.2008
   PubMed Web of Science ®Google Scholar
• Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57(8):988–996. doi:10.1002/jcph.887
   PubMed Web of Science ®Google Scholar
• Tran JQ, Hartung JP, Olson AD, et al. Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT/QTc Study. Clin Pharmacol Drug Dev. 2018;7(3):263–276. doi:10.1002/cpdd.383
   PubMed Web of Science ®Google Scholar
• Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471–480. doi:10.1177/1352458513500551
   PubMed Web of Science ®Google Scholar
• Surapaneni S, Yerramilli U, Bai A, et al. Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator. Drug Metab Dispos. 2021;49(5):405–419. doi:10.1124/dmd.120.000220
   PubMed Web of Science ®Google Scholar
• Tran JQ, Zhang P, Ghosh A, et al. Single-dose pharmacokinetics of ozanimod and its major active metabolites alone and in combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: a Randomized, Parallel-Group, Open-Label Study. Adv Ther. 2020;37(10):4381–4395. doi:10.1007/s12325-020-01473-0
   PubMed Web of Science ®Google Scholar
• Squibb BM. Zeposia ® (ozanimod) Full Prescribing Information. Available from: https://packageinserts.bms.com/pi/pi_zeposia.pdf. Accessed August 8, 2022.
   Google Scholar
• Tran JQ, Hartung JP, Tompkins CA, Frohna PA. Effects of high- and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine-1-phosphate receptor modulator. Clin Pharmacol Drug Dev. 2018;7(6):634–640. doi:10.1002/cpdd.409
   PubMed Web of Science ®Google Scholar
• Jairath V, Peyrin-Biroulet L, Zou G, et al. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019;68(7):1162–1168. doi:10.1136/gutjnl-2018-316702
   PubMed Web of Science ®Google Scholar
• Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–761. doi:10.1016/j.jval.2017.02.005
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–1255.e8. doi:10.1016/j.cgh.2016.01.015
   PubMed Web of Science ®Google Scholar
• Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20(3):564–575. doi:10.1097/01.MIB.0000437986.00190.71
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12(6):929–34.e2. doi:10.1016/j.cgh.2013.07.022
   PubMed Web of Science ®Google Scholar
• Squibb BM. U.S. food and drug administration approves Bristol Myers squibb’s Zeposia® (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis. Available from: https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1/default.aspx. Accessed May 27, 2022.
   Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. doi:10.1056/NEJMoa0904492
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine NIoH. A study of efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (VEGA). Available from: https://clinicaltrials.gov/ct2/show/NCT03662542. Accessed July 28, 2022.
   Google Scholar